Skip to main content

Table 2 Treatment regimen for patients with CRE infection

From: Molecular epidemiology and outcome of carbapenem-resistant Enterobacterales in Saudi Arabia

Variable n (%)
Any carbapenem (meropenem, imipenem, ertapenem) 131 (69.3)
Aminoglycoside (amikacin, gentamicin) 38 (20.1)
Aztreonam 11 (5.8)
CAZ-AVI 89 (47.1)
Colistin 78 (41.3)
Tigecycline 62 (32.8)
  1. CAZ-AVI ceftazidime-avibactam